umifenovir: CDRI achieves breakthrough in trial of Umifenovir in Covid-19 treatment | India News

LUCKNOW: The Central Drug Research Institute (CDRI) on Tuesday claimed that the clinical trials of antiviral drug, Umifenovir, in treatment of Covid-19 have been successful.
The trial of Umifenovir on 132 Covid-19 patients showed that, if the proper dose is given twice daily for five days, the drug can effectively reduce viral load in mild or moderate symptomatic and asymptomatic patients by checking multiplication of the virus.
Titled ‘Phase III, randomized, double-blind, placebo-controlled trial of efficacy, safety and tolerability of antiviral drug Umifenovir vs standard care of therapy in non-severe Covid-19 patients’, the clinical trial was conducted at three institutions – King George’s Medical University (KGMU), Ram Manohar Lohia Institute of Medical Sciences (RMLIMS) and Era’s Lucknow Medical College and Hospital (ELMCH).
“Since Umifenovir is a broad-spectrum…

Source link


Please enter your comment!
Please enter your name here